Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

By M. Postow, M. Callahan, C. Barker, Y. Yamada, Jianda Yuan, S. Kitano, Z. Mu, T. Rasalan, Matthew Adamow, E. Ritter and 11 more. New England Journal of Medicine, 2012

1,966 citations recorded by the source corpus.

Summary The abscopal effect is a phenomenon in which local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site. The abscopal effect may be mediated by activation of the immune system. Ipilimumab is a monoclonal antibody that inhibits an immunologic checkpoint on T cells, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). We report a case of the abscopal effect in a patient with melanoma treated with ipilimumab and radiotherapy. Temporal associations were noted: tumor shrinkage with antibody responses to the cancer–testis antigen NY-ESO-1, changes in peripheral-blood immune cells, and increases in antibody responses to other antigens after radiotherapy. (Funded by the National Institutes of Health and others.)

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/c0f3f61577a915851bfe24f1c6e31ce608e52155

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. E. Golden
2. S. Formenti
3. S. Demaria
4. Zhijian J. Chen
5. J. Wolchok
6. A. Chachoua
7. Xiao-Dong Li
8. M. Postow

In Oncology

1. J. Wolchok
2. E. Golden
3. S. Formenti
4. S. Demaria
5. M. Postow
6. A. Chachoua
7. K. Schindler
8. L. Connell

Citations in the corpus

• STING-dependent Cytosolic DNA Sensing Promotes Radiation-induced Type I interferon-dependent Antitumor Immunity in Immunogenic Tumors (2014, background): “Based on this concept, the blockade of immune checkpoints improves the I efficacy of radiotherapy on local and distant tumors in experimental systems and more recently in clinical observations (Deng et al., 2014; Postow et al., 2012).”
• Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Anti-Tumor Immune Responses via Cross-Presentation of Tumor Antigen (2014, background): “Moreover, several clinical case reports provide evidence of synergy between combined XRT and immune checkpoint blockade (29, 30).”
• Immunology and Immunotherapy of Head and Neck Cancer. (2015, background): “Combination PD-1 blockade and anti-CD137 stimulation increased response to RT in a mouse model of triplenegative breast cancer,100 and PD-L1 blockade concomitant with RT improved survival in comparison with either therapy alone in mouse models of glioma.101 In humans, case reports support the existe”
• Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. (2016, neutral): “Prior systemic therapies 2-3 15 (48) 6 (26) 12 (44) 4-5 7 (23) 9 (39) 8 (30) $ 6 5 (16) 5 (22) 6 (22)”
• Combining radiotherapy and cancer immunotherapy: a paradigm shift. (2013, background): “Importantly, a recent case of an abscopal effect of radiotherapy after clinical progression on ipilimumab in a melanoma patient (118) mimics the synergy demonstrated in preclinical studies of local radiation and anti-CTLA-4 (107,108).”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Combining RT and immunotherapy may create opportunities to synergize these effects, as well as generate an antitumor effect outside the irradiated field, termed the abscopal effect [103, 104].”